Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Amele, S, Peters, L, Rodger, A, Lundgren, J, Rockstroh, J, Matulionyte, R, Leen, C, Jabłonowska, E, Østergaard, L, Bhagani, S, Sarcletti, M, Clarke, A, Falconer, K, Wandeler, G, Domingo, P, Maltez, F, Zaccarelli, M, Chkhartisvili, N, Szlavik, J, Stephan, C, Fonquernie, L, Aho, I & Mocroft, A 2021, 'Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study' Journal of acquired immune deficiency syndromes (1999), bind 86, nr. 2, s. 248-257. https://doi.org/10.1097/QAI.0000000000002541

APA

CBE

Amele S, Peters L, Rodger A, Lundgren J, Rockstroh J, Matulionyte R, Leen C, Jabłonowska E, Østergaard L, Bhagani S, Sarcletti M, Clarke A, Falconer K, Wandeler G, Domingo P, Maltez F, Zaccarelli M, Chkhartisvili N, Szlavik J, Stephan C, Fonquernie L, Aho I, Mocroft A. 2021. Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study. Journal of acquired immune deficiency syndromes (1999). 86(2):248-257. https://doi.org/10.1097/QAI.0000000000002541

MLA

Vancouver

Author

Amele, Sarah ; Peters, Lars ; Rodger, Alison ; Lundgren, Jens ; Rockstroh, Jϋrgen ; Matulionyte, Raimonda ; Leen, Clifford ; Jabłonowska, Elzbieta ; Østergaard, Lars ; Bhagani, Sanjay ; Sarcletti, Mario ; Clarke, Amanda ; Falconer, Karolin ; Wandeler, Gilles ; Domingo, Pere ; Maltez, Fernando ; Zaccarelli, Mauro ; Chkhartisvili, Nikoloz ; Szlavik, Janos ; Stephan, Christoph ; Fonquernie, Laurent ; Aho, Inka ; Mocroft, Amanda. / Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons : Results from a pan-European study. I: Journal of acquired immune deficiency syndromes (1999). 2021 ; Bind 86, Nr. 2. s. 248-257.

Bibtex

@article{d5cc6ff56e43472f89952741b81ebd78,
title = "Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study",
abstract = "OBJECTIVES: To investigate the effectiveness, safety and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/HCV co-infected individuals in Europe.METHODS: All HIV/HCV co-infected individuals in the EuroSIDA study that started interferon (IFN) free DAA treatment between 1/6/2014 and 1/3/2018 with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.RESULTS: 1042 individuals started IFN-free DAA treatment after 1/6/2014 and were included, 862 (82.2{\%}) had a known response to treatment, 789 (91.5{\%}, 95{\%} CI 89.7-93.4) of which achieved SVR12. There were no differences in SVR12 across regions of Europe (p=0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir +/- RBV (aOR 0.21 (95{\%} CI 0.08-0.53) or ombitasvir/paritaprevir/dasabuvir +/- RBV (aOR 0.46 (95{\%} CI 0.22-1.00) compared to sofosbuvir/ledipasvir +/- RBV. 43 (4.6{\%}) individuals had one or more components of their HCV regimen stopped early, most commonly due to toxicity (n=14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n=15.3{\%}) and was related to treatment with atazanavir and ribavirin.CONCLUSIONS: Our findings from real-world data on HIV/HCV co-infected individuals across Europe show DAA treatment is well tolerated, and that high rates of SVR12 can be achieved in all regions of Europe.",
author = "Sarah Amele and Lars Peters and Alison Rodger and Jens Lundgren and Jϋrgen Rockstroh and Raimonda Matulionyte and Clifford Leen and Elzbieta Jabłonowska and Lars {\O}stergaard and Sanjay Bhagani and Mario Sarcletti and Amanda Clarke and Karolin Falconer and Gilles Wandeler and Pere Domingo and Fernando Maltez and Mauro Zaccarelli and Nikoloz Chkhartisvili and Janos Szlavik and Christoph Stephan and Laurent Fonquernie and Inka Aho and Amanda Mocroft",
year = "2021",
month = "2",
day = "1",
doi = "10.1097/QAI.0000000000002541",
language = "English",
volume = "86",
pages = "248--257",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons

T2 - Results from a pan-European study

AU - Amele, Sarah

AU - Peters, Lars

AU - Rodger, Alison

AU - Lundgren, Jens

AU - Rockstroh, Jϋrgen

AU - Matulionyte, Raimonda

AU - Leen, Clifford

AU - Jabłonowska, Elzbieta

AU - Østergaard, Lars

AU - Bhagani, Sanjay

AU - Sarcletti, Mario

AU - Clarke, Amanda

AU - Falconer, Karolin

AU - Wandeler, Gilles

AU - Domingo, Pere

AU - Maltez, Fernando

AU - Zaccarelli, Mauro

AU - Chkhartisvili, Nikoloz

AU - Szlavik, Janos

AU - Stephan, Christoph

AU - Fonquernie, Laurent

AU - Aho, Inka

AU - Mocroft, Amanda

PY - 2021/2/1

Y1 - 2021/2/1

N2 - OBJECTIVES: To investigate the effectiveness, safety and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/HCV co-infected individuals in Europe.METHODS: All HIV/HCV co-infected individuals in the EuroSIDA study that started interferon (IFN) free DAA treatment between 1/6/2014 and 1/3/2018 with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.RESULTS: 1042 individuals started IFN-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, 789 (91.5%, 95% CI 89.7-93.4) of which achieved SVR12. There were no differences in SVR12 across regions of Europe (p=0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir +/- RBV (aOR 0.21 (95% CI 0.08-0.53) or ombitasvir/paritaprevir/dasabuvir +/- RBV (aOR 0.46 (95% CI 0.22-1.00) compared to sofosbuvir/ledipasvir +/- RBV. 43 (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly due to toxicity (n=14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n=15.3%) and was related to treatment with atazanavir and ribavirin.CONCLUSIONS: Our findings from real-world data on HIV/HCV co-infected individuals across Europe show DAA treatment is well tolerated, and that high rates of SVR12 can be achieved in all regions of Europe.

AB - OBJECTIVES: To investigate the effectiveness, safety and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/HCV co-infected individuals in Europe.METHODS: All HIV/HCV co-infected individuals in the EuroSIDA study that started interferon (IFN) free DAA treatment between 1/6/2014 and 1/3/2018 with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.RESULTS: 1042 individuals started IFN-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, 789 (91.5%, 95% CI 89.7-93.4) of which achieved SVR12. There were no differences in SVR12 across regions of Europe (p=0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir +/- RBV (aOR 0.21 (95% CI 0.08-0.53) or ombitasvir/paritaprevir/dasabuvir +/- RBV (aOR 0.46 (95% CI 0.22-1.00) compared to sofosbuvir/ledipasvir +/- RBV. 43 (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly due to toxicity (n=14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n=15.3%) and was related to treatment with atazanavir and ribavirin.CONCLUSIONS: Our findings from real-world data on HIV/HCV co-infected individuals across Europe show DAA treatment is well tolerated, and that high rates of SVR12 can be achieved in all regions of Europe.

U2 - 10.1097/QAI.0000000000002541

DO - 10.1097/QAI.0000000000002541

M3 - Journal article

VL - 86

SP - 248

EP - 257

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -

ID: 61064175